Cargando…
Current clinical challenges in prostate cancer
Prostate cancer is the most common malignancy and the second leading cause of cancer death in men in the United States. Close to $12 billion are spent annually on the treatment of prostate cancer in the US alone. Yet still there remain tremendous controversies and challenges that exist in all facets...
Autores principales: | Silberstein, Jonathan L., Pal, Sumanta Kumar, Lewis, Brian, Sartor, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708189/ https://www.ncbi.nlm.nih.gov/pubmed/26816735 http://dx.doi.org/10.3978/j.issn.2223-4683.2013.09.03 |
Ejemplares similares
-
Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Pal, Sumanta Kumar, et al.
Publicado: (2010) -
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Long-term survival of participants in the prostate cancer prevention trial
por: Silberstein, Jonathan L, et al.
Publicado: (2014) -
Management of localized prostate cancer: the pendulum swings (back to the middle)
por: Vuong, Winston, et al.
Publicado: (2014) -
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
por: Ramnaraign, Brian, et al.
Publicado: (2023)